These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31635225)

  • 1. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
    Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
    Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
    PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
    Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
    Lu Y; Liu Y; Lan J; Chan YT; Feng Z; Huang L; Wang N; Pan W; Feng Y
    J Adv Res; 2023 Sep; 51():181-196. PubMed ID: 36351536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma.
    Ito R; Miyanishi K; Kubo T; Hamaguchi K; Osuga T; Tanaka S; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Mizuguchi T; Takemasa I; Kato J
    Hepatol Int; 2023 Jun; 17(3):735-744. PubMed ID: 36738397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
    Tang C; Du Y; Liang Q; Cheng Z; Tian J
    Mol Imaging Biol; 2020 Jun; 22(3):476-485. PubMed ID: 31228075
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Liu TP; Hong YH; Yang PM
    Oncotarget; 2017 Oct; 8(49):86168-86180. PubMed ID: 29156785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.
    Lutz L; Fitzner IC; Ahrens T; Geißler AL; Makowiec F; Hopt UT; Bogatyreva L; Hauschke D; Werner M; Lassmann S
    Am J Cancer Res; 2016; 6(3):664-76. PubMed ID: 27152243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
    Buurman R; Sandbothe M; Schlegelberger B; Skawran B
    Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
    Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
    Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
    Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
    Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
    Yang CX; Bao F; Zhong J; Zhang L; Deng LB; Sha Q; Jiang H
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10194-10202. PubMed ID: 33090427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma.
    Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC
    Front Oncol; 2022; 12():1009089. PubMed ID: 36185276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
    Garmpis N; Damaskos C; Garmpi A; Georgakopoulou VE; Sarantis P; Antoniou EA; Karamouzis MV; Nonni A; Schizas D; Diamantis E; Koustas E; Farmaki P; Syllaios A; Patsouras A; Kontzoglou K; Trakas N; Dimitroulis D
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.